Review Article

Astragalus-based Chinese traditional medicine combined with chemotherapy for non-small-cell lung cancer treatment: meta-analysis of randomized trials

Ai Yue¹, Yong-Li Guo¹*, Guo-Xia Wang¹, Ying-Jin Zhang², Tao-Li Sun³, Si-Fang Zhang², Zhe Wang²

¹Department of Oncology, The First People’s Hospital of Jining City, Jining 272000, Shandong, P. R. China; ²Department of Integrated Chinese and Western Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, P. R. China; ³Department of Pharmacy, School of Pharmacy, Changsha Medical University, Changsha 410200, Hunan, P. R. China. *Equal contributors.

Received March 9, 2016; Accepted September 8, 2016; Epub November 15, 2016; Published November 30, 2016

Abstract: Purpose: Chemotherapy represents one of the major treatments for non-small-cell lung cancer (NSCLC), while its drug resistance and high toxicity raise big concerns. Astragalus-based Chinese traditional patent medicine combined with chemotherapy was frequently used for treatment of NSCLC in China. However, its effectiveness hasn’t been systematically analyzed. The present study aimed to evaluate the benefits of Astragalus-based Chinese traditional patent medicine combined with chemotherapy for NSCLC. Methods: The randomized controlled trials involving NSCLC treatment with Astragalus-based Chinese traditional patent medicine combined with chemotherapy were screened. The Review Manager 5.3 software was employed for data analysis. Funnel plot were applied to evaluate publication bias. Results: 15 eligible studies met our criteria. 15 studies indicated increase tumor response. 8, 6, and 4 studies revealed reduced toxicity including leucopenia, thrombopenia, nausea and vomiting, respectively. Conclusion: Astragalus-based Chinese traditional patent medicine may benefit the treatment of NSCLC through increasing effectiveness and reducing the toxicity of chemotherapy. More full-scale randomized clinical trials and long-term effectiveness are recommended to further evaluate for treatment of NSCLC.

Keywords: Astragalus, chemotherapy, NSCLC, meta-analysis

Introduction

Cancer has emerged as a major global public health problem with the incidence and mortality rates continue to rise. Moreover, non-small-cell lung cancer (NSCLC) is the lead cause of cancer mortality. Its treatment constitutes a constant challenge to surgeons [1]. Like many other cancers, chemotherapy represents one of the major treatments for NSCLC, which aims to kill cancer cells or to inhibit their proliferation. However, the same effect also acts on normal cells which would results in unpredicted toxicity. What’s more, long-term use of chemotherapy drugs could induce drug resistance. Therefore, the major challenges for treatment of NSCLC chemotherapy are drug resistance and dose-dependent toxicity [2].

In recent years, the use of complementary and alternative medicine (CAM) gradually becomes an effective means to attenuate drug resistance and toxicity of chemotherapy. Traditional Chinese medicine (TCM) has been used to treat cancer for thousands of years in China, Japan, and other Asian countries [3]. Numerous preclinical and clinical studies have demonstrated that TCM combined with chemotherapy could provide an effective treatment for NSCLC [4]. Astragalus is one of these TCM and Astragalus-based Chinese traditional patent medicine has been accepted as current form of CAM in NSCLC. Astragalus (Radix Astragali in Latin), a perennial herbaceous plant of the Leguminosae, is widely distributed in the temperate region. It has been used in China for more than 2000 years and documented in an ancient book called Shennong Bencao Jing in AD 200 [5]. The dried root of Astragalus possesses extensive pharmacological activities against cardiovascular disease, hepatitis, kidney disease [6]. More
Astragalus combined with chemotherapy for NSCLC

than 100 bioactive compounds in Astragalus have been reported including polysaccharides, flavonoids, astragalosides and aminoacids [7], which may lead to increased sensitivity of chemotherapy and reduced side effects of chemotherapy when Astragalus-based Chinese traditional patent medicine combined with chemotherapy.

To date, studies on the effects of Astragalus-based Chinese traditional patent medicine combined with chemotherapy on NSCLC have been extensively explored. However, the result remains inconclusive and conflicting. To the best of our knowledge, the evidence for the effect of Astragalus-based Chinese traditional patent medicine combined with chemotherapy on NSCLC has not been systematically assessed. In the present study, a meta-analysis was performed to get a more concise estimation on effect of Astragalus-based Chinese traditional patent medicine combined with chemotherapy on NSCLC.

Methods

Inclusion criteria

Studies included in the meta-analysis had to meet all of the following criteria. (1) Participants: NSCLC patients had to be diagnosed by pathological sections and were treated by chemotherapy. (2) Type of studies: only clinical randomized controlled trials (RCTs) were eligible. (3) Type of intervention: studies provided the treatment group with Astragalus-containing Chinese traditional patent medicine in combination with chemotherapy and the control group with chemotherapy alone were included for analysis. (4) Type of outcome measurements: tumor response was the main outcome measurements, other outcome measurements included remission in the toxicity of chemotherapy, such as the inhibition of nausea and vomiting, leucopenia and thrombopenia, were also investigated.

Figure 1. Flow diagram showing the trial selection process for the systematic review.
Astragalus combined with chemotherapy for NSCLC

Table 1. Characteristics of the eligible studies

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Stage</th>
<th>Protocol</th>
<th>Herbel ingredients</th>
<th>Duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Magnolia obavata, Fritillaria cirrhosa, Semen Lepidii, Cortex mori radices, Aster.</td>
<td></td>
</tr>
<tr>
<td>Peng et al., 2010 [12]</td>
<td>100</td>
<td>III-IV</td>
<td>AP+NP</td>
<td>Astragalus, radix curcuma, Rithoma Curcuma, Prunella vulgaris, Raw oyster shell, Hedyotis diffusa, Nidus vespae, Heterophylla falsestarwort root.</td>
<td>8-9</td>
</tr>
<tr>
<td>Qiao, 2012 [13]</td>
<td>60</td>
<td>II-IV</td>
<td>AP+TP</td>
<td>Astragalus, Radix codonopsis.</td>
<td>6</td>
</tr>
<tr>
<td>Wang et al., 2004 [14]</td>
<td>60</td>
<td>III-IV</td>
<td>AP+VP</td>
<td>Astragalus injection</td>
<td>8-9</td>
</tr>
<tr>
<td>Zhong, 2011 [16]</td>
<td>80</td>
<td>NR</td>
<td>AP+NP</td>
<td>Astragalus injection</td>
<td>6-8</td>
</tr>
<tr>
<td>Zheng et al., 2012 [18]</td>
<td>95</td>
<td>IV</td>
<td>AP+NP</td>
<td>Astragalus polysaccharide injection</td>
<td>12</td>
</tr>
<tr>
<td>Zhao et al., 2011 [19]</td>
<td>60</td>
<td>IIIb-IV</td>
<td>AP+TP</td>
<td>Astragalus, Fructus lycii, Heterophylla falsestarwort root, Arisacma consanguineum, Alum processed pinellia, almond, Hedyotis diffusa.</td>
<td>6</td>
</tr>
<tr>
<td>Xu et al., 2006 [24]</td>
<td>63</td>
<td>II-IV</td>
<td>AP+NP</td>
<td>Astragalus, Adenophora stricta, Radix ophiopogonis, Polygonatum odoratum, Heterophylla falsestarwort root, Cordyceps sinensis, Hedyotis diffusa, Radix Stephaniae Tetrandrae, Mulberry leaf, Panax notoginseng, Radix fici hirtae.</td>
<td>8</td>
</tr>
<tr>
<td>Shao et al., 2011 [21]</td>
<td>60</td>
<td>IIIb-IV</td>
<td>AP+NP</td>
<td>Astragalus, Atractylodes macrocephala koidz, Poria cocos, Scrophulariae, Radix ophiopogonis, Bile arisaema, Selaginella doederleinii, Salvia chinensis, Hedyotis diffusa, Raw oyster shell, Trichosanthes ovigera, Gecko.</td>
<td>6</td>
</tr>
<tr>
<td>Qin et al., 2009 [18]</td>
<td>64</td>
<td>IIIb-IV</td>
<td>AP+GP</td>
<td>Astragalus polysaccharide injection</td>
<td>6</td>
</tr>
<tr>
<td>Zhang et al., 2013 [22]</td>
<td>60</td>
<td>III-IV</td>
<td>AP+TP</td>
<td>Astragalus polysaccharide injection</td>
<td>6</td>
</tr>
<tr>
<td>Li et al., 2008 [23]</td>
<td>98</td>
<td>III-IV</td>
<td>AP+NP/TP</td>
<td>Astragalus polysaccharide injection</td>
<td>6-8</td>
</tr>
</tbody>
</table>

Abbreviations: AP: Astragalus prescription; GP: gemcitabine, cisplatin; NP, vinorelbine, cisplatin; TP: taxol, cisplatin; VP: vindesine, cisplatin; CAP, cyclophosphamide, doxorubicin, cisplatin; MVP, mitomycin, vindesine, cisplatin; MAP, mitomycin, doxorubicin, cisplatin.
Astragalus combined with chemotherapy for NSCLC

Data extraction and quality assessment

Two reviewers (Ai Yue and Yong-Li Guo) independently extracted data on patient characteristics, treatment details, clinical outcomes, and study quality [8]. Any disagreements were resolved by consensus or by a third reviewer (Guo-Xia Wang). Methodological quality of included studies was assessed independently by two review authors (Ai Yue and Yong-Li Guo) with the criteria in the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [9]. Sequence generation, allocation concealment, blinding method, selective outcome reporting, incomplete data assessment, and other sources of bias were assessed with three potential responses: yes, no and unclear. The differences were resolved by consensus or referral to a third reviewer (Tao-Li Sun).

Data analysis

Data analysis was conducted by Review Manager 5.3 software (http://www.cochrane.org/). The results were reported as relative risk (RR) with 95% confidence interval (CI). A random model was applied when the heterogeneity existed in pooled studies ($I^2 > 50\%$), otherwise, the fix model was applied. A probability value $<0.05$ ($P<0.05$) was considered significant. Funnel plot the potential publication bias was investigated and expressed as Funnel plot if the number of trials available was more than ten for a meta-analysis [9].

Outcome measures

Tumor response was calculated as the number of patients with complete response (CR) plus partial response (PR) based on the WHO scale [10] divided by the total number of patients in each treatment group. Chemotherapy toxicity was investigated including nausea and vomiting, leucopenia and thrombopenia. Leucopenia and thrombopenia was calculated as the number of patients with reduction of leucocyte and platelet respectively divided by the total number of patients in each treatment group. Nausea and vomiting was calculated as the number of patients with symptom of nausea and vomiting divided by the total number of patients in each treatment group.
Astragalus combined with chemotherapy for NSCLC

Results

Description of studies

318 articles were screened out as shown in Figure 1 after primary search from the 6 databases, of which 194 were identified as requiring relevant abstracts or title retrieval. Close screening of the 194 abstracts excluded 144 due to inappropriate controls (n = 11), non-clinical studies (n = 23), no clinical curative effect evaluation (n = 25), Astragalus was not used as principal medicine (n = 28), containing Astragalus but not Chinese traditional patent medicines (n = 30), duplicate publication (n = 10), and no chemotherapy (n = 17). 50 full-text articles were further screened for eligibility. 35 articles were excluded because of not for treating NSCLC (n = 22), and less than 60 patients (n = 13). Therefore, the total of 15 articles were found to be eligible and accepted for the current meta-analysis.

Characteristics of the eligible studies

The included trials enrolled 1333 patients with NSCLC, of which 680 received Chinese traditional patent medicine treatment. As shown in Table 1, all of 15 eligible studies [11-23] were conducted in China and were published between 1999 and 2013 in Chinese journals. The stages of NSCLC patients recruited in these studies were as follows: 6 [11, 12, 14, 15, 22, 23], 4 [13, 17, 24], 3 [18, 19, 21], 1 [25] studies were at III to IV, II to IV, III b to IV, IV, respectively. 1 [16] study did not mention the stage condition. These studies involved 7 kinds of chemotherapeutic drug combinations as follows: GP (gemcitabine, cisplatin), NP (vinorelbine, cisplatin), TP (taxol, cisplatin), VP (vinorelbine, cisplatin), CAP (cyclophosphamide, doxorubicin, cisplatin), MVP (mitomycin, vindesine, cisplatin), and MAP (mitomycin, doxorubicin, cisplatin). The durations of the treatments varied from 3 to 12 weeks in the included studies, and most of durations were 6-9 weeks.

Outcome measures

Tumor response

15 Studies [11-23] including 1333 patients that reported the tumor response were identified in Figure 2. The analytical results with fixed effects model (homogeneity, chi-square = 8.28, I² = 0%, P = 0.87) demonstrated that the combination treatment of Astragalus-containing Chinese traditional patent medicine with chemotherapy was associated with a significant increase in the number of patients reported complete and partial response when compared with the chemotherapy alone group (RR 1.40; 95% CI, 1.22 to 1.61). The symmetry of the funnel plot indicated no significant publication bias (Figure 3).

Reduction in chemotherapy-induced leucopenia

Leucopenia is one of the main side effects that chemotherapy resulted in. As can be seen in Figure 4, 8 studies [11-13, 17, 18, 20, 24, 25] including 848 patients which were detected the amount of leucocyte in blood. The 8 trials showed homogeneity (chi-square = 11.83, I² = 41%, P = 0.11), and fixed-effects model was used. The combination treatment with Astragalus-containing Chinese traditional patent medicine plus chemotherapy significantly reduced the number of patients with the leucopenia when compared with the chemotherapy alone.
Astragalus combined with chemotherapy for NSCLC

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Astragalus-based Chinese herbs + chemotherapy</th>
<th>Chemotherapy alone</th>
<th>Weight</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu et al., 2001</td>
<td>11 events 60 total</td>
<td>18 events 100 total</td>
<td>0.7%</td>
<td>0.68 (0.53, 1.16)</td>
<td>0.73 (0.51, 1.05)</td>
</tr>
<tr>
<td>Peng et al., 2010</td>
<td>10 events 50 total</td>
<td>10 events 27 total</td>
<td>19.6%</td>
<td>0.37 (0.20, 0.69)</td>
<td>0.40 (0.24, 0.67)</td>
</tr>
<tr>
<td>Gao et al., 2012</td>
<td>4 events 30 total</td>
<td>5 events 30 total</td>
<td>3.6%</td>
<td>0.90 (0.24, 3.68)</td>
<td>0.13 (0.02, 0.64)</td>
</tr>
<tr>
<td>Qin et al., 2009</td>
<td>13 events 32 total</td>
<td>18 events 32 total</td>
<td>13.8%</td>
<td>0.77 (0.63, 0.95)</td>
<td>0.73 (0.52, 0.91)</td>
</tr>
<tr>
<td>Xu et al., 2006</td>
<td>1 events 30 total</td>
<td>6 events 30 total</td>
<td>5.8%</td>
<td>0.13 (0.02, 0.64)</td>
<td>0.13 (0.02, 0.64)</td>
</tr>
<tr>
<td>Zhang et al., 1999</td>
<td>20 events 65 total</td>
<td>43 events 79 total</td>
<td>30.0%</td>
<td>0.73 (0.52, 1.01)</td>
<td>0.73 (0.52, 1.01)</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>287 events 366 total</td>
<td>137 total</td>
<td>100%</td>
<td>0.62 (0.49, 0.77)</td>
<td>0.62 (0.49, 0.77)</td>
</tr>
</tbody>
</table>

Figure 5. Thrombopenia with Astragalus-containing Chinese herbal combined with chemotherapy.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Astragalus-based Chinese herbs + chemotherapy</th>
<th>Chemotherapy alone</th>
<th>Weight</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu et al., 2001</td>
<td>17 events 100 total</td>
<td>17 events 47 total</td>
<td>40.4%</td>
<td>0.33 (0.20, 0.56)</td>
<td>0.33 (0.20, 0.56)</td>
</tr>
<tr>
<td>Peng et al., 2010</td>
<td>19 events 50 total</td>
<td>19 events 32 total</td>
<td>26.1%</td>
<td>0.59 (0.39, 0.89)</td>
<td>0.59 (0.39, 0.89)</td>
</tr>
<tr>
<td>Gao et al., 2012</td>
<td>11 events 30 total</td>
<td>11 events 22 total</td>
<td>18.0%</td>
<td>0.50 (0.30, 0.84)</td>
<td>0.50 (0.30, 0.84)</td>
</tr>
<tr>
<td>Qin et al., 2009</td>
<td>11 events 32 total</td>
<td>19 events 32 total</td>
<td>15.5%</td>
<td>0.58 (0.33, 1.01)</td>
<td>0.58 (0.33, 1.01)</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>212 events 262 total</td>
<td>120 total</td>
<td>100%</td>
<td>0.47 (0.37, 0.65)</td>
<td>0.47 (0.37, 0.65)</td>
</tr>
</tbody>
</table>

Figure 6. Nausea and vomiting with Astragalus-containing Chinese herbal combined with chemotherapy versus chemotherapy alone.

alone group (RR 0.53; 95% CI, 0.46 to 0.61). The number of studies reporting performance status was less than ten, so a funnel plot was not applicable.

Reduction in chemotherapy-induced thrombopenia

Chemotherapy frequently induces platelet descend, also called thrombopenia. We identified 7 [11-13, 17, 18, 20, 24, 25] studies including 753 patients which were detected the amount of platelet in blood (Figure 5). The 7 trials showed homogeneity (chi-square = 6.91, $I^2 = 13\%$, $P = 0.33$). The statistical analysis with fixed-effects model revealed that Astragalus-containing Chinese traditional patent medicine plus chemotherapy had a significant decrease in the number of patients with thrombopenia when compared with the chemotherapy alone group (RR 0.62; 95% CI, 0.49 to 0.77). The number of studies reporting performance status was less than ten, so a funnel plot was not applicable.

Reduction in chemotherapy-induced nausea and vomiting

Chemotherapy also induces nausea and vomiting. As shown in Figure 6, 4 studies including 414 patients which were observed the symptom of nausea and vomiting. As the 4 [12, 13, 17, 18] trials showed homogeneity (chi-square = 4.17, $I^2 = 28\%$, $P = 0.24$), the fixed-effects model was used for statistical analysis. The results revealed that the patients with the combination treatment of Astragalus-containing Chinese traditional patent medicine plus chemotherapy showed significantly less patients with nausea and vomiting compared with the chemotherapy alone group (RR 0.47; 95% CI, 0.37 to 0.59). The number of studies reporting performance status was less than ten, so a funnel plot was not applicable.

Discussion

Although numerous studies have reported the anticancer activity of Astragalus, however, the exact anticancer active substances in Astragalus are rarely reported. Astragalus abounds polysaccharides, flavonoids, saponins, polysaccharides, amino acids, and other compounds [7]. The polysaccharides, saponins, andflavonoids may be the major anti-tumor constituents of Astragalus [6]. Astragalus polysaccharides exerted a synergistic anti-tumor effect with adriamycin on H22 tumor-bearing mice. It could alleviate the decrease in the sizes of the spleen and thymus induced by Adriamycin [26]. Astragaloside IV and II, two kinds of active saponins, have been shown the potential anti-
Astragalus combined with chemotherapy for NSCLC

tumor activity against liver cancer [27, 28]. Total flavonoids of Astragalus and calycosin could also inhibit the proliferation of K562 cells [29]. As shown in Figure 7, some compounds from Astragalus have been demonstrated the antioxidant and immunomodulatory activity [7], their anticancer activities deserve further study.

The antioxidant activities of Astragalus has been widely reported in vitro due to its considerable scavenging activities against hydroxyl-radical, 1, 1-diphenyl-2 picrylhydrazyl radical, super oxideanion, and hydrogenperoxide [30-32]. What’s more, Astragalus could increase the number of lymphocytes to active both cellular and humoral immune response [33]. Numerous studies both in vivo and vitro have certified the immunomodulatory effects of Astragalus [34, 35]. It is well known that the immunosuppression and free radicals are two main factors to inducing the formation and development of cancer [36]. Therefore, antioxidant and immunomodulatory effects of Astragalus may be the mechanism on synergistic effect of Astragalus-based Chinese traditional patent medicine combined with chemotherapy against cancer.

In the present study, 15 studies with 318 individuals suffering from NSCLC were screened out. The results suggested that Astragalus-
based Chinese traditional patent medicine combined with chemotherapy in the treatment of NSCLC may increase tumor response and reduce the side effect including leucopenia, thrombopenia, nausea and vomiting when compared with the chemotherapy alone. Those effects of Astragalus-based Chinese traditional patent medicine might directly associate with the benefits to NSCLC. However, in order to clarify the herbal prescriptions function when combined with chemotherapy, the specific mechanisms and bioactive components of herbal prescriptions may be the focus of future studies. All of studies were only based on the information of short-term effectiveness. There was few data on the long-term effectiveness of treatment provided for analysis. Meanwhile, in view of the generally weak methodological quality of the currently included studies, we are unable to make solid conclusions, and confirmation must await investigation in future trials.

It has to be acknowledged that there are several limitations in the study. Most of trials didn’t report an exact randomization method. It wasn’t clear that whether placebo controlled and blinded assessors were set, whereas drop-outs and withdrawals were not mentioned in any study. Moreover, of all used anti-cancer drugs were chemotherapeutic drugs, but the drug combinations and types were different. Hence, performance bias would be inevitable. Moreover, publication bias indicated by funnel plots was another limitation of present study. Just because of discussion as above-mentioned, it is essential to improve methodological quality of randomized controlled trials for future study and more methodologically rigorous studies are justified to confirm or refute the present study.

In conclusion, we found evidence that Astragalus-based Chinese traditional patent medicine combined with chemotherapy in the treatment of NSCLC may increase effectiveness (by improving the tumor response) and reduce the toxicity of chemotherapy (by attenuating leucopenia, thrombopenia, nausea and vomiting). However, more full-scale randomized clinical trials and long-term effectiveness are required before more firm conclusions about this therapy can be drawn for treatment of NSCLC.

Acknowledgements

The present work was supported by a grant from Hunan Province Traditional Chinese medicine scientific research project (No. 201242, and NO. 201413).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Ying-Jin Zhang, Department of Integrated Chinese and Western Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, P. R. China. E-mail: yjzhangdream@sina.com

References

Astragalus combined with chemotherapy for NSCLC


Astragalus combined with chemotherapy for NSCLC

analysis and bioactivity of a polysaccharide from the roots of Astragalus (Fisch) Bge. var. mongolicus (Bge.) Hsiao. Food Chem 2011; 128: 620-6.


[34] Li SP, Zhao XJ, Wang JY. Synergy of Astragalus polysaccharides and probiotics (Lactobacillus and Bacillus cereus) on immunity and intestinal microbiota in chicks. Poultry Science 2009; 88: 519-25.
